Smith & Nephew plc (NYSE:SNN) is one of the best robotic surgery stocks to buy.
Bernstein cut the price target on Smith & Nephew plc (NYSE:SNN) to $31.85 from $36.20 on May 11, maintaining a Market Perform rating on the shares
The rating update came after the company provided a fiscal Q1 trading update on May 6, with the firm noting that reported sales were up 3.1% organically, missing consensus growth of 3.8%. Smith & Nephew plc (NYSE:SNN) also received a rating update from Canaccord the same day, with the firm cutting the price target on the stock to $30 from $32 and maintaining a Hold rating on the shares. The firm updated its model on the stock after its fiscal Q1 results to take into account comp-group compression.
In its financial results for fiscal Q1 2026, Smith & Nephew plc (NYSE:SNN) reported revenue of $1,501 million, with underlying revenue growth of 3.1%, and reported revenue growth of 6.6%, which included a 350bps foreign exchange tailwind. Smith & Nephew plc (NYSE:SNN) develops, manufactures, markets, and sells medical devices. Its operations are divided into the following segments: Orthopedics, Sports Medicine and ENT, and Advanced Wound Management.